Hepta Announces Blood-Based Assay for GLP-1 Response Precision Medicine
Hepta has unveiled a blood-based assay that identifies epigenetic signatures associated with GLP-1 responses. This breakthrough aims to enable precision medicine in treating obesity and MASH, addressing a critical gap in predicting patient response to weight loss therapies before treatment initiation and monitoring biological changes during therapy.
FOSTER CITY, Calif.–(BUSINESS WIRE)–GLP-1 medicines are being prescribed for weight loss at a scale the healthcare system has never managed before. Clinicians can measure weight loss. What they still cannot see, in any scalable, non-invasive way, is which patients are biologically positioned to respond before treatment begins, or how therapy is changing disease biology once it starts. Hepta today announced data at Digestive Disease Week 2026 showing that a blood-based assay analyzing cell-fre